美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · SRPT近 30 天 14 則 · 第 1 / 1 頁
- Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
- Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
- Novartis Stock Tanks Following Third Major Pipeline Setback
- Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
- Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
- Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
- Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
- Moderna Stock Carries A Market Value Its Revenue Does Not Support
- Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value
- Moderna Stock Had A Readout Waiting In Plain Sight
- KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
- Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
- Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling
- Moderna's Melanoma Result Landed On A Market Positioned The Other Way
- Sarepta (SRPT) Q2 2026 Earnings Call Transcript
- Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
- Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says
- Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates
- Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。